IP Library Granted Patent US 12,006,338
Granted Patent B2
US 12,006,338 · App. 18/087,555 · Granted Jun 11, 2024

Antimicrobial organosilanes

Inventors: Gary Allred (Wake Forest, NC); Lanny Liebeskind (Atlanta, GA); William R. Cast (Fort Wayne, IN); Carl Hilliard (Henderson, NV)
Assignee: Topikos Scientific, Inc.
C07F7/1896
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,006,338
App. No.
18/087,555
Granted
Jun 11, 2024
Kind
B2
Abstract

Organosilicon quaternary ammonium compounds, their formulations, including powdered and solid formulations, and methods of use to treat infections in humans and animals.

Claims (51)

1. A quaternary ammonium compound of Formula:

or pharmaceutically acceptable salt thereof,

wherein

a is 3;

R 1 is independently at each occurrence selected from the group consisting of C 6 -C 22 alkyl and C 6 -C 22 alkanoyl;

R 2 , R 3 , and R 4 are independently at each occurrence selected from the group consisting of:

R 8 is H or CH 2 OH;

R 9 is H or C 1 -C 8 alkyl,

X 3 is OH or CH 2 OR 7 ;

R 10 , R 11 , and R 12 are independently at each occurrence selected from the group consisting of hydrogen, —CH 2 OR 7 , CON(R 7 ) 2 , COOR 7 , C(O)R 7 , C 1 -C 8 alkyl, C 1 -C 8 hydroxyalkyl, and C 1 -C 8 alkanoyl;

R 13 is selected from the group consisting of CH 2 OR 7 , CON(R 7 ) 2 , COOR 7 , C(O)R 7 , C 1 -C 8 alkyl, C 1 -C 8 hydroxyalkyl, and C 1 -C 8 alkanoyl;

R 7 is independently at each occurrence selected from hydrogen, C 1 -C 8 alkyl, C 1 -C 8 hydroxyalkyl, and C 1 -C 8 alkanoyl;

X 1 is NR 17 , CH 2 , or C(O);

X 4 is selected from the group consisting of hydroxyl, CH 2 OR 7 , CON(R 7 ) 2 , COOR 7 , C(O)R 7 , C 1 -C 8 hydroxyalkyl, and C 1 -C 8 alkanoyl;

R 16 is C 1 -C 4 alkyl;

R 17 is hydrogen, C 1 -C 8 hydroxyalkyl, or C 1 -C 8 alkanoyl;

X − is an anion.

2. The quaternary ammonium compound of claim 1 , wherein X − is selected from the group consisting of chloride, fluoride, iodide, bromide, hydroxide, chlorite, chlorate, hydroxide, formate, acetate, lactate, benzoate, methane sulfonate and salicylate anion.

3. The quaternary ammonium compound of claim 1 , wherein R 2 , R 3 , and R 4 are

and X 3 is OH.

4. The quaternary ammonium compound of claim 1 , wherein R 2 , R 3 , and R 4 are

and R 8 is CH 2 OH and R 9 is C 1 -C 8 alkyl.

5. The quaternary ammonium compound of claim 4 , wherein X 4 is OH and X 1 is C(O).

6. The quaternary ammonium compound of claim 4 , wherein R 1 is octadecyl and R 16 is CH 3 .

7. The quaternary ammonium compound of claim 4 , wherein X 4 is OH and X 1 is CH 2 .

8. The quaternary ammonium compound of claim 1 selected from the group consisting of:

9. The quaternary ammonium compound of claim 8 of structure:

10. The quaternary ammonium compound of claim 8 of structure:

11. The quaternary ammonium compound of claim 8 of structure:

12. The quaternary ammonium compound of claim 8 of structure:

13. An antimicrobial composition comprising a quaternary ammonium compound selected from the group consisting of:

and a pharmaceutically acceptable carrier.

14. The antimicrobial composition according to claim 13 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of alcohol, aqueous solution, and glycerin solution.

15. The antimicrobial composition of claim 13 , wherein the composition is suitable for topical delivery.

16. The antimicrobial composition of claim 13 , wherein the quaternary ammonium compound is

17. The antimicrobial composition of claim 13 , wherein the quaternary ammonium compound is

18. The antimicrobial composition of claim 13 , wherein the quaternary ammonium compound is

19. The antimicrobial composition of claim 13 , wherein the quaternary ammonium compound is

20. The antimicrobial composition of claim 13 , wherein the quaternary ammonium compound is

21. The antimicrobial composition of claim 13 , wherein the quaternary ammonium compound is

22. The quaternary ammonium compound of claim 1 selected from the group consisting of:

wherein anion X − is a methane sulfonate anion.

23. The antimicrobial composition according to claim 13 , wherein the pharmaceutically acceptable carrier is an aqueous solution.

24. An antimicrobial composition comprising a quaternary ammonium compound selected from the group consisting of:

and a pharmaceutically acceptable carrier;

wherein anion X − is a methane sulfonate anion.

25. The antimicrobial composition of claim 24 , wherein the quaternary ammonium compound is

wherein anion X − is a methane sulfonate anion.

26. The antimicrobial composition according to claim 24 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of alcohol, aqueous solution, and glycerin solution.

27. The antimicrobial composition of claim 24 , wherein the composition is suitable for topical delivery.

28. The antimicrobial composition according to claim 24 , wherein the pharmaceutically acceptable carrier is an aqueous solution.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2024
From: LIEBESKIND, LANNY; CAST, WILLIAM R.; HILLIARD, CARL
To: TOPIKOS SCIENTIFIC, INC.
Reel/Frame 067326/0019 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2024
From: ALLRED, GARY
To: SYNTHONIX, INC.
Reel/Frame 067326/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2024
From: SYNTHONIX, INC.
To: TOPIKOS SCIENTIFIC, INC.
Reel/Frame 067326/0051 →
CHANGE OF NAME Recorded Mar 28, 2023
From: TOPIKOS PHARMACEUTICALS, INC.
To: TOPIKOS SCIENTIFIC, INC.
Reel/Frame 063185/0928 →
Continuity (5)
Continuation 17723168 · Apr 18, 2022
Continuation PCTUS2020056392 · Oct 19, 2020
Provisional Application 63014535 · Apr 23, 2020
Provisional Application 62923372 · Oct 18, 2019
Related Publication 20230295195A1 · Sep 21, 2023
Cited By (1)
US 12,264,170